Implications of growth factor alterations in the treatment of pancreatic cancer
<p>Abstract</p> <p>Pancreatic cancer ranks fifth as a cause of cancer-related death in the world with an overall 5-year survival rate of less than 1% and a median survival of less than a year after tumour detection. Most of these patients have already metastases at the time of diag...
Main Authors: | Malfertheiner Peter, Nitsche Barbara, Juhász Márk, Ebert Matthias PA |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2003-01-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://www.molecular-cancer.com/content/2/1/5 |
Similar Items
-
Effects of STI571 (gleevec) on pancreatic cancer cell growth
by: Büchler Markus W, et al.
Published: (2003-09-01) -
Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
by: Chen-Yu Hu, et al.
Published: (2019-12-01) -
Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib
by: Jung Hun Ohn, et al.
Published: (2013-06-01) -
Target Therapy Using a Small Molecule Inhibitor against Angiogenic Receptors in Pancreatic Cancer
by: Peter Büchler, et al.
Published: (2007-02-01) -
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
by: Alessandro Di Federico, et al.
Published: (2021-07-01)